Unleashing Innovation: The Role of Bispecific Antibodies in Managing Diffuse Large B-Cell Lymphoma
| Target Professions: | DO, MD, Nurse, Nurse Practitioner, Pharmacist, Physician Assistant |
| Target Specialties: | Hematology, Hematology/Oncology, Oncology |
| Credits Available: | 4.25 AMA PRA Category 1 Credit™/ MOC Points |
This dynamic course empowers clinicians to elevate care for DLBCL patients by connecting them with CAR-T therapy experts for real-time education and mentoring. Through interactive small-group sessions, accessible online activities, and practical tools, participants will gain the confidence and skills to refine their management approaches and achieve superior patient outcomes. Join us to build a supportive, interprofessional network and drive impactful improvements in DLBCL care, creating a ripple effect of CAR-T expertise across the country.
CME/CE Accreditation Information
Itinerary
Part 1
The following questions will assess your baseline knowledge of DLBCL.
This module discusses clinical practice guideline third-line treatment recommendations for R/R DLBCL and the safety and efficacy data from clinical trials of epcoritamab and glofitamab, as well as patient eligibility considerations for these agents via a patient case discussion.
This module discusses the signs and symptoms of toxicities associated with bispecifics used in the treatment of R/R DLBCL and describes protocols for managing CRS and ICANS in this patient population.
Welcome to our module on improving collaboration between community providers and cancer centers to expand bispecific antibody use. Our faculty will discuss strategies to ensure access, focusing on practical approaches to overcome barriers and enhance outcomes.
Now that you have reviewed the self-study modules, answer the following questions to assess your gained knowledge of DLBCL.
We will dive into pivotal DLBCL-specific insights from each module, engaging in lively discussions on challenge submissions and sharing valuable feedback and comments.
Part 2
This activity features a 55-year-old woman with R/R DLBCL who is being treated with glofitamab.
This activity features a 63-year-old man with R/R DLBCL who presents to determine his best option for third-line treatment.
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with DLBCL.
We will discuss key points specific to DLBCL from each of the preceding modules, as well as answer any questions in an interactive discussion.
